The control over KRAS expression and activity in glioblastomas suggests that let-7 can regulate RAS activity even without oncogenic mutation and that this may be a general phenomenon related to the interactions between tumour suppressor genes (let-7) and proto-oncogenes (KRAS). The gene discussed is KRAS; the disease is neoplasm.